SG Americas Securities LLC Acquires 8,848 Shares of Haemonetics Corporation (NYSE:HAE)

SG Americas Securities LLC increased its holdings in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 510.9% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,580 shares of the medical instruments supplier's stock after purchasing an additional 8,848 shares during the quarter. SG Americas Securities LLC's holdings in Haemonetics were worth $672,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Arizona State Retirement System grew its stake in shares of Haemonetics by 1.2% in the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock valued at $1,160,000 after buying an additional 181 shares in the last quarter. CWC Advisors LLC. grew its position in Haemonetics by 7.4% in the fourth quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock valued at $241,000 after acquiring an additional 212 shares in the last quarter. Vise Technologies Inc. grew its position in Haemonetics by 8.7% in the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after acquiring an additional 225 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares during the period. Finally, HighTower Advisors LLC lifted its position in shares of Haemonetics by 7.8% during the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after purchasing an additional 244 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

HAE has been the subject of a number of analyst reports. Wall Street Zen downgraded Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. JMP Securities reiterated a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research note on Tuesday, May 20th. Needham & Company LLC decreased their price target on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, Raymond James Financial reaffirmed a "strong-buy" rating and issued a $105.00 price target (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $97.89.

Haemonetics Price Performance

Haemonetics stock traded up $1.18 during midday trading on Tuesday, hitting $73.25. The company's stock had a trading volume of 459,933 shares, compared to its average volume of 677,983. The stock's 50-day moving average price is $66.49 and its 200-day moving average price is $68.33. The company has a market capitalization of $3.52 billion, a PE ratio of 22.13, a price-to-earnings-growth ratio of 1.15 and a beta of 0.36. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. Haemonetics Corporation has a 12 month low of $55.30 and a 12 month high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The company had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The company's quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.90 EPS. Analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.